Cyclica (acquired by Recursion, Nasdaq: RXRX)
Biotechnology ResearchCanada51-200 Employees
Cyclica has been acquired by Recursion! Please follow @Recursion on LinkedIn and @RecursionPharma on Twitter to receive updates on our next chapter.
AI Innovation Synergies Cyclica's recent acquisition by Recursion and its focus on biotechnology research position it at the forefront of AI-driven drug discovery, presenting opportunities to collaborate on innovative AI platforms or expand into integrated biotech solutions.
Market Expansion Potential With Beacons AI, Inc. launching new products like Beacons for Brands and establishing integrated marketplaces, there is a clear trajectory towards content monetization and brand engagement, ideal for SaaS providers or marketing tech solutions seeking new customer segments.
Financial Scalability Although Cyclica and its peers operate with revenues between $1M and $10M, the recent funding and strategic acquisitions suggest capacity for scaling operations, creating sales opportunities for scalable enterprise solutions or financial investment services.
Customer Engagement Opportunities The focus on content creator monetization and new brand integration demonstrates a growing need for engagement platforms, analytics tools, and customer relationship management solutions tailored to digital marketing and creator economy businesses.
Technology & Data Adoption Cyclica utilizes a broad tech stack including Profitwell, Chargebee, and social media integrations, indicating openness to adopting new SaaS tools, APIs, and analytics services that enhance data-driven decision-making or optimize operational efficiency.
Cyclica (acquired by Recursion, Nasdaq: RXRX) uses 8 technology products and services including Profitwell, cdnjs, Canny, and more. Explore Cyclica (acquired by Recursion, Nasdaq: RXRX)'s tech stack below.
| Cyclica (acquired by Recursion, Nasdaq: RXRX) Email Formats | Percentage |
| First.Last@cyclicarx.com | 100% |
| First@beacons.ai | 85% |
| Last@beacons.ai | 14% |
| FirstL@beacons.ai | 1% |
Biotechnology ResearchCanada51-200 Employees
Cyclica has been acquired by Recursion! Please follow @Recursion on LinkedIn and @RecursionPharma on Twitter to receive updates on our next chapter.
Cyclica (acquired by Recursion, Nasdaq: RXRX) has raised a total of $6M of funding over 1 rounds. .
Cyclica (acquired by Recursion, Nasdaq: RXRX)'s revenue is estimated to be in the range of $1M$10M
Cyclica (acquired by Recursion, Nasdaq: RXRX) has raised a total of $6M of funding over 1 rounds. .
Cyclica (acquired by Recursion, Nasdaq: RXRX)'s revenue is estimated to be in the range of $1M$10M